PL3813942T3 - Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek - Google Patents
Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerekInfo
- Publication number
- PL3813942T3 PL3813942T3 PL19796519.7T PL19796519T PL3813942T3 PL 3813942 T3 PL3813942 T3 PL 3813942T3 PL 19796519 T PL19796519 T PL 19796519T PL 3813942 T3 PL3813942 T3 PL 3813942T3
- Authority
- PL
- Poland
- Prior art keywords
- centhaquin
- treating
- salt
- composition
- kidney function
- Prior art date
Links
- UJNWGFBJUHIJKK-UHFFFAOYSA-N 2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline Chemical compound CC1=CC=CC(N2CCN(CCC=3N=C4C=CC=CC4=CC=3)CC2)=C1 UJNWGFBJUHIJKK-UHFFFAOYSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000007423 decrease Effects 0.000 title 1
- 230000003907 kidney function Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666675P | 2018-05-03 | 2018-05-03 | |
| IN201841019588 | 2018-05-25 | ||
| PCT/US2019/030652 WO2019213558A1 (en) | 2018-05-03 | 2019-05-03 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3813942T3 true PL3813942T3 (pl) | 2024-07-22 |
Family
ID=68386694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19796519.7T PL3813942T3 (pl) | 2018-05-03 | 2019-05-03 | Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210169978A1 (pl) |
| EP (2) | EP3813942B1 (pl) |
| JP (1) | JP7458032B2 (pl) |
| CN (1) | CN112469474A (pl) |
| AU (1) | AU2019262612B2 (pl) |
| BR (1) | BR112020022395A2 (pl) |
| ES (1) | ES2978951T3 (pl) |
| PL (1) | PL3813942T3 (pl) |
| WO (1) | WO2019213558A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010241564B2 (en) | 2009-04-30 | 2014-07-31 | Midwestern University | Novel therapeutic treatments using centhaquin |
| JP2024517334A (ja) * | 2021-05-11 | 2024-04-19 | ファーマズ，インコーポレイテッド | コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法 |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| US20240382461A1 (en) * | 2023-05-15 | 2024-11-21 | Pharmazz, Inc. | Pharmaceutical composition and method for prevention and treatment of hearing loss |
| IN202411028038A (pl) * | 2024-04-04 | 2025-05-23 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0597891A (ja) * | 1991-04-24 | 1993-04-20 | Banyu Pharmaceut Co Ltd | 血管弛緩ペプチド類 |
| CA2578709C (en) * | 2004-06-17 | 2010-06-15 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| JP2009506119A (ja) * | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| US20080242687A1 (en) * | 2007-04-02 | 2008-10-02 | Auspex Pharmaceuticals, Inc. | Substituted pyrimidines |
| AU2008237062A1 (en) | 2007-04-10 | 2008-10-16 | Auspex Pharmaceuticals, Inc. | Substituted deuterium enriched thiophenes for the treatment of hypertension |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| AU2010241564B2 (en) * | 2009-04-30 | 2014-07-31 | Midwestern University | Novel therapeutic treatments using centhaquin |
| US20130296331A1 (en) | 2010-11-26 | 2013-11-07 | Technion Research And Development Foundation Ltd. | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
| BR112015004643A2 (pt) | 2012-08-31 | 2017-07-04 | Univ Midwestern | métodos e composições para ressucitação hipotensiva |
| AU2014287427B2 (en) | 2013-07-08 | 2019-11-21 | Midwestern University | Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist |
-
2019
- 2019-05-03 PL PL19796519.7T patent/PL3813942T3/pl unknown
- 2019-05-03 AU AU2019262612A patent/AU2019262612B2/en active Active
- 2019-05-03 EP EP19796519.7A patent/EP3813942B1/en active Active
- 2019-05-03 ES ES19796519T patent/ES2978951T3/es active Active
- 2019-05-03 WO PCT/US2019/030652 patent/WO2019213558A1/en not_active Ceased
- 2019-05-03 JP JP2020561786A patent/JP7458032B2/ja active Active
- 2019-05-03 BR BR112020022395-6A patent/BR112020022395A2/pt not_active Application Discontinuation
- 2019-05-03 US US17/052,473 patent/US20210169978A1/en active Pending
- 2019-05-03 CN CN201980038669.0A patent/CN112469474A/zh active Pending
- 2019-05-03 EP EP24163271.0A patent/EP4364811A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3813942A1 (en) | 2021-05-05 |
| JP2021523125A (ja) | 2021-09-02 |
| EP3813942A4 (en) | 2022-01-19 |
| AU2019262612B2 (en) | 2025-04-03 |
| AU2019262612A1 (en) | 2020-11-26 |
| WO2019213558A1 (en) | 2019-11-07 |
| CA3099128A1 (en) | 2019-11-07 |
| US20210169978A1 (en) | 2021-06-10 |
| CN112469474A (zh) | 2021-03-09 |
| JP7458032B2 (ja) | 2024-03-29 |
| ES2978951T3 (es) | 2024-09-23 |
| EP3813942B1 (en) | 2024-04-17 |
| BR112020022395A2 (pt) | 2021-04-13 |
| EP4364811A2 (en) | 2024-05-08 |
| EP4364811A3 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3813942T3 (pl) | Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek | |
| IL277551A (en) | Tri-specific binding molecules against cancer and their uses | |
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| IL277343B1 (en) | "CD47-binding factors and their uses in the treatment of diseases" | |
| SG11202106605VA (en) | Compounds that participate in cooperative binding and uses thereof | |
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| GB201802201D0 (en) | Binding agents | |
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| IL290692A (en) | Salt | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| EP3997667A4 (en) | MEMORY IN ANIMATED AGENTS | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL280368A (en) | Compounds for use in the treatment of kidney disorders | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| GB201804094D0 (en) | ERBB3 Binding agents | |
| IL276914A (en) | CSF1R binding factors | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| SG11202100269VA (en) | Compounds for use in the treatment of fascioliasis | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| ZA202004991B (en) | New spirooxathiolanone compounds, their preparation method as well as their use in perfume-making and aromatics industry | |
| SG11202103435RA (en) | Agent for reducing the phosphate concentration in wastewater | |
| GB201809458D0 (en) | Salt form | |
| GB201809460D0 (en) | Salt form |